Expert: Implementing CED Differently Could Help Boost Innovation

A top industry expert tells Inside Health Policy CMS’ coverage with evidence development (CED) process can play a positive role in the drug development industry by serving as a tool to demonstrate the value for therapies and products and ultimately boost innovation. CMS, however, sees the model as mainly aimed at ensuring drugs work for older patients with comorbidities, and a former agency official says it’s likely to become less significant with another model in use to evaluate accelerated...